Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients

Jarrett J. Failing, Yiyi Yan, Luis F. Porrata, Svetomir Nenad Markovic

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The peripheral blood lymphocyte-to-monocyte ratio (LMR) has been associated with prognosis in many malignancies including metastatic melanoma. However, it has not been studied in patients treated with immune checkpoint inhibitors. In this study, we analyzed the baseline LMR with progression-free survival (PFS) and overall survival (OS) in metastatic melanoma patients treated with pembrolizumab. A total of 133 patients with metastatic melanoma treated with pembrolizumab were included in this retrospective study. LMR was calculated from pretherapy peripheral blood counts and the optimal cutoff value was determined by a receiver operator characteristic curve. PFS and OS were evaluated using the Kaplan-Meier method and multivariate Cox proportional hazard modeling. Patients with an LMR of at least 1.7 showed improved PFS (hazard ratio=0.55; 95% confidence interval: 0.34-0.92; P=0.024) and OS (hazard ratio=0.29; 95% confidence interval: 0.15-0.59; P=0.0007). The baseline LMR is associated with PFS and OS in metastatic melanoma patients treated with pembrolizumab, and could represent a convenient and cost-effective prognostic biomarker. Validation of these findings in an independent cohort is needed.

Original languageEnglish (US)
Pages (from-to)596-600
Number of pages5
JournalMelanoma Research
Volume27
Issue number6
DOIs
StatePublished - Jan 1 2017

Fingerprint

Monocytes
Melanoma
Disease-Free Survival
Lymphocytes
Survival
Confidence Intervals
Retrospective Studies
Biomarkers
pembrolizumab
Costs and Cost Analysis
Neoplasms

Keywords

  • Biomarker
  • Lymphocytes
  • Melanoma
  • Monocytes
  • Pembrolizumab

ASJC Scopus subject areas

  • Oncology
  • Dermatology
  • Cancer Research

Cite this

Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients. / Failing, Jarrett J.; Yan, Yiyi; Porrata, Luis F.; Markovic, Svetomir Nenad.

In: Melanoma Research, Vol. 27, No. 6, 01.01.2017, p. 596-600.

Research output: Contribution to journalArticle

@article{7a7cddaf3d3648c98f6f336da77883c4,
title = "Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients",
abstract = "The peripheral blood lymphocyte-to-monocyte ratio (LMR) has been associated with prognosis in many malignancies including metastatic melanoma. However, it has not been studied in patients treated with immune checkpoint inhibitors. In this study, we analyzed the baseline LMR with progression-free survival (PFS) and overall survival (OS) in metastatic melanoma patients treated with pembrolizumab. A total of 133 patients with metastatic melanoma treated with pembrolizumab were included in this retrospective study. LMR was calculated from pretherapy peripheral blood counts and the optimal cutoff value was determined by a receiver operator characteristic curve. PFS and OS were evaluated using the Kaplan-Meier method and multivariate Cox proportional hazard modeling. Patients with an LMR of at least 1.7 showed improved PFS (hazard ratio=0.55; 95{\%} confidence interval: 0.34-0.92; P=0.024) and OS (hazard ratio=0.29; 95{\%} confidence interval: 0.15-0.59; P=0.0007). The baseline LMR is associated with PFS and OS in metastatic melanoma patients treated with pembrolizumab, and could represent a convenient and cost-effective prognostic biomarker. Validation of these findings in an independent cohort is needed.",
keywords = "Biomarker, Lymphocytes, Melanoma, Monocytes, Pembrolizumab",
author = "Failing, {Jarrett J.} and Yiyi Yan and Porrata, {Luis F.} and Markovic, {Svetomir Nenad}",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/CMR.0000000000000404",
language = "English (US)",
volume = "27",
pages = "596--600",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients

AU - Failing, Jarrett J.

AU - Yan, Yiyi

AU - Porrata, Luis F.

AU - Markovic, Svetomir Nenad

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The peripheral blood lymphocyte-to-monocyte ratio (LMR) has been associated with prognosis in many malignancies including metastatic melanoma. However, it has not been studied in patients treated with immune checkpoint inhibitors. In this study, we analyzed the baseline LMR with progression-free survival (PFS) and overall survival (OS) in metastatic melanoma patients treated with pembrolizumab. A total of 133 patients with metastatic melanoma treated with pembrolizumab were included in this retrospective study. LMR was calculated from pretherapy peripheral blood counts and the optimal cutoff value was determined by a receiver operator characteristic curve. PFS and OS were evaluated using the Kaplan-Meier method and multivariate Cox proportional hazard modeling. Patients with an LMR of at least 1.7 showed improved PFS (hazard ratio=0.55; 95% confidence interval: 0.34-0.92; P=0.024) and OS (hazard ratio=0.29; 95% confidence interval: 0.15-0.59; P=0.0007). The baseline LMR is associated with PFS and OS in metastatic melanoma patients treated with pembrolizumab, and could represent a convenient and cost-effective prognostic biomarker. Validation of these findings in an independent cohort is needed.

AB - The peripheral blood lymphocyte-to-monocyte ratio (LMR) has been associated with prognosis in many malignancies including metastatic melanoma. However, it has not been studied in patients treated with immune checkpoint inhibitors. In this study, we analyzed the baseline LMR with progression-free survival (PFS) and overall survival (OS) in metastatic melanoma patients treated with pembrolizumab. A total of 133 patients with metastatic melanoma treated with pembrolizumab were included in this retrospective study. LMR was calculated from pretherapy peripheral blood counts and the optimal cutoff value was determined by a receiver operator characteristic curve. PFS and OS were evaluated using the Kaplan-Meier method and multivariate Cox proportional hazard modeling. Patients with an LMR of at least 1.7 showed improved PFS (hazard ratio=0.55; 95% confidence interval: 0.34-0.92; P=0.024) and OS (hazard ratio=0.29; 95% confidence interval: 0.15-0.59; P=0.0007). The baseline LMR is associated with PFS and OS in metastatic melanoma patients treated with pembrolizumab, and could represent a convenient and cost-effective prognostic biomarker. Validation of these findings in an independent cohort is needed.

KW - Biomarker

KW - Lymphocytes

KW - Melanoma

KW - Monocytes

KW - Pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85032790352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032790352&partnerID=8YFLogxK

U2 - 10.1097/CMR.0000000000000404

DO - 10.1097/CMR.0000000000000404

M3 - Article

VL - 27

SP - 596

EP - 600

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 6

ER -